ACC.26丨聚焦肥胖管理新進展，前瞻即將發(fā)布的重要研究！

肥胖已成為全球公共衛(wèi)生領(lǐng)域面臨的重大挑戰(zhàn)之一，不僅與2型糖尿病、高血壓、血脂異常等多種代謝性疾病密切相關(guān)，也是心血管疾病發(fā)生發(fā)展的重要危險因素。近年來，隨著代謝機制研究的深入以及新型減重藥物的不斷涌現(xiàn)，肥胖管理正迎來快速發(fā)展的新階段，從藥物治療到綜合干預(yù)策略，多項創(chuàng)新研究持續(xù)推動臨床實踐的更新與優(yōu)化。北京時間3月28日至30日，備受矚目的ACC.26學術(shù)會議將在美國新奧爾良盛大召開。作為心血管領(lǐng)域的國際盛會，本次大會將公布多項與肥胖及體重管理相關(guān)的最新研究成果。POCKETIN特別整理了大會中值得關(guān)注的肥胖領(lǐng)域相關(guān)日程，帶大家提前了解即將發(fā)布的重要研究亮點。

03月28日

1301. Featured Fields 01
北京時間：22:30
ASSOCIATION OF OBESITY AND MYOCARDIAL RECOVERY OF PERIPARTUM CARDIOMYOPATHY
肥胖與圍產(chǎn)期心肌病心肌恢復(fù)的關(guān)聯(lián)

Anvitha Addanki

1302. Cardiovascular Disease Prevention 01
北京時間：22:30
TIRZEPATIDE VERSUS GLP-1 RECEPTOR AGONISTS IN OBESE ADULTS WITHOUT DIABETES: REAL-WORLD CARDIOMETABOLIC OUTCOMES
替爾泊肽對比GLP-1受體激動劑在非糖尿病肥胖成人中的真實世界心臟代謝結(jié)局

A. Bahar

北京時間：22:30
CAGRISEMA VERSUS CAGRILINTIDE OR SEMAGLUTIDE MONOTHERAPY AS ANTI-OBESITY MEDICATIONS: A SYSTEMATIC REVIEW AND BAYESIAN NETWORK META-ANALYSIS WITH TRIAL SEQUENTIAL ANALYSIS
卡格列美肽對比卡格列那肽或司美格魯肽單藥作為抗肥胖藥物：一項系統(tǒng)評價與貝葉斯網(wǎng)狀薈萃分析及試驗序貫分析

Sima Rawal

1323. Heart Failure and Cardiomyopathies 01
北京時間：22:30
GLP-1 RECEPTOR AGONISTS IN HEART FAILURE WITH REDUCED/MILDLY REDUCED EF: 5-YEAR OUTCOMES AND EFFECT MODIFICATION BY OBESITY AND ETHNICITY
GLP-1受體激動劑在射血分數(shù)降低/輕度降低的心力衰竭中的應(yīng)用：5年結(jié)局及肥胖與種族的效應(yīng)修飾

H. Agarwal

03月29日

1030. ACC Complex Clinical Cases: Heart Failure and Cardiomyopathies (Session 2)
北京時間：00:12
ORTHOSTATIC HYPERTENSIVE EMERGENCY IN HFPEF WITH OBESITY: A NOVEL ACUTE CARE CASE SERIES
肥胖合并射血分數(shù)保留的心力衰竭中的直立性高血壓急癥：一項新型急癥病例系列

T. Lovell

1325. Featured Fields 02
北京時間：00:00
GLUCAGON-LIKE PEPTIDE RECEPTOR-1 RECEPTOR AGONISTS IN METABOLICALLY-HEALTHY MORBIDLY-OBESE: A PROPENSITY-SCORE MATCHED ANALYSIS
胰高血糖素樣肽-1受體激動劑在代謝健康的重度肥胖患者中的應(yīng)用：一項傾向評分匹配分析

R. Vempati

1326. Cardiovascular Disease Prevention 02
北京時間：00:00
GENETICALLY DEFINED ENDOTYPES MODIFY THE EFFECTS OF LIFESTYLE ON OBESITY: EVIDENCE FOR PRECISION PREVENTION
基因定義的內(nèi)型改變生活方式對肥胖的影響：精準預(yù)防的證據(jù)

Devesh Malik

北京時間：00:00
LEAN MASS LOSS ASSOCIATED WITH THE USE OF GLP-1 AND GLP-1/GIP AGONISTS IN THE TREATMENT OF OBESITY
使用GLP-1及GLP-1/GIP激動劑治療肥胖相關(guān)的瘦體重下降

Kaliana Almeida, MD, CCRP

1330. Multimodal Imaging 02
北京時間：00:00
PROGNOSTIC VALUE OF LATE GADOLINIUM ENHANCEMENT FOR FIRST HEART FAILURE HOSPITALIZATION AFTER STRESS CMR IN SEVERE OBESITY
嚴重肥胖患者負荷心臟磁共振后首次心力衰竭住院的晚期釓增強預(yù)后價值

Qiuyu Zhu

北京時間：00:00
PREVALENCE AND PROGNOSTIC IMPACT OF UNRECOGNIZED MYOCARDIAL INFARCTION DETECTED BY CARDIAC MAGNETIC RESONANCE IN PATIENTS WITH OBESITY
肥胖患者中經(jīng)心臟磁共振檢出的未被識別心肌梗死的患病率及預(yù)后影響

Punyanuch Chayanopparat

1347. Heart Failure and Cardiomyopathies 02
北京時間：00:00
INFLAMMATORY OBESITY AND HEART FAILURE IN BLACK ADULTS: INSIGHTS FROM THE JACKSON HEART STUDY
黑人成人中的炎癥性肥胖與心力衰竭：來自杰克遜心臟研究的見解

Syed Sarmad Javaid

北京時間：00:00
GEOGRAPHIC VARIATION IN PREVALENCE OF OBESITY IN HFMREF/HFPEF: IMPORTANCE OF ANTHROPOMETRIC INDEX USED AND ETHNICITY-ADJUSTMENT
射血分數(shù)降低/保留的心力衰竭患者中肥胖患病率的地域差異：所用人體測量指數(shù)及種族校正的重要性

Ryohei Ono

1032. Collaborative Cardiovascular Team Solutions for Complex Cases
北京時間：01:54
SUPRA-THERAPEUTIC BUT SUB-THERAPUETIC AFTERALL? NAVIGATING ANTICOAGULATION FOR VENOUS THROMBOEMBOLISM IN A MORBIDLY OBESE HIGH-RISK PATIENT
超治療范圍卻又亞治療？——在病態(tài)肥胖高危患者中管理靜脈血栓栓塞抗凝治療

H. Lim

1041. Therapeutic Shifts in EP: Novel Agents, Acute Conversion and Precision DOACs
北京時間：02:06
GLUCAGON-LIKE PEPTIDE-1 AGONISTS AND THE INCIDENCE OF ATRIAL FIBRILLATION IN NON-DIABETIC OBESE PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION
胰高血糖素樣肽-1激動劑與非糖尿病肥胖射血分數(shù)保留心力衰竭患者心房顫動發(fā)生率的關(guān)系

Farah Rassam

1042. Unpacking HFpEF With Proteomics, Metabolism and Microvascular Mechanisms
北京時間：02:18
HEIGHTENED IMPACT OF CORONARY MICROVASCULAR DYSFUNCTION IN HEART FAILURE WITH PRESERVED EJECTION FRACTION IN THE ABSENCE OF OBESITY
在無肥胖的情況下，冠狀動脈微血管功能障礙對射血分數(shù)保留的心力衰竭的影響加劇

K. Nogami

1355. Cardiac Arrhythmias 03
北京時間：01:30
IMPACT OF MORBID OBESITY ON OUTCOMES OF TRANSVENOUS LEAD EXTRACTION
病態(tài)肥胖對經(jīng)靜脈導(dǎo)線拔除結(jié)局的影響

K. Sawalha

1057. New Horizons in AFib Care: GLP-1, SGLT2, DOACs and LAAO
北京時間：03:00
EFFECT OF GLP-1 RECEPTOR AGONISTS ON ARRHYTHMIA RISK IN OBESE PATIENTS WITHOUT DIABETES: A LARGE-SCALE REAL-WORLD ANALYSIS
GLP-1受體激動劑對非糖尿病肥胖患者心律失常風險的影響：一項大規(guī)模真實世界分析

A.-R. A. Ottun

1395. Heart Failure and Cardiomyopathies 04
北京時間：03:00
IMPACT OF OBESITY ON CARDIOVASCULAR OUTCOMES IN MAVACAMTEN-TREATED HYPERTROPHIC CARDIOMYOPATHY: A PROPENSITY-MATCHED ANALYSIS
肥胖對接受Mavacamten治療的肥厚型心肌病心血管結(jié)果的影響：傾向評分匹配分析

Rebecca Adler

1065. Heart and More
北京時間：04:42
SEX-SPECIFIC CARDIOVASCULAR BURDEN ATTRIBUTABLE TO OVERWEIGHT AND OBESITY IN PARAGUAY: TRENDS FROM 2011 TO 2022
巴拉圭超重與肥胖相關(guān)的性別特異性心血管負擔：2011年至2022年趨勢

Giuliana Cattivelli Murdoch

1066. Unmasking Hidden Risk: From Calcium to Flow in Contemporary Coronary Assessment
北京時間：05:18
OBESITY IS ASSOCIATED WITH FASTER CORONARY ARTERY CALCIUM PROGRESSION AMONG STATIN USERS
肥胖與他汀類藥物使用者中冠狀動脈鈣化進展加快相關(guān)

D. Budoff

1068. Nutrient Stimulated Hormone Therapies For Metabolic Health and Weight Management
北京時間：04:54
BENEFITS OF BARIATRIC SURGERY VERSUS GLP-1 AGONISTS ON MORTALITY, CARDIOVASCULAR DISEASE, SLEEP APNEA, AND DEMENTIA
減重手術(shù)對比GLP-1激動劑在死亡率、心血管疾病、睡眠呼吸暫停及癡呆方面的獲益

I. Mortada

北京時間：05:06
REVISITING THE OBESITY PARADOX IN ISCHEMIC HEART DISEASE: OUTCOMES AFTER PCI IN PATIENTS ON GLP-1 AGONISTS
再探缺血性心臟病中的肥胖悖論：使用GLP-1激動劑的患者經(jīng)皮冠狀動脈介入治療后的結(jié)局

Viraj Shah

1397. Featured Fields 05
北京時間：04:30
OBESITY AND DIASTOLIC DYSFUNCTION: UNDERLYING HEMODYNAMIC MECHANISMS
肥胖與舒張功能不全：潛在的血流動力學機制

Deniz Rafiei

1400. Ischemic Heart Diseases 05
北京時間：04:30
PROGNOSTIC IMPLICATIONS OF CORONARY MICROVASCULAR DYSFUNCTION IN ST-ELEVATION MYOCARDIAL INFARCTION BY OBESITY STATUS
基于肥胖狀態(tài)的冠狀動脈微血管功能障礙對ST段抬高型心肌梗死患者的預(yù)后影響

Q. Guo 北京

1403. Cardiac Arrhythmias 05
北京時間：04:30
INCIDENCE OF ARRHYTHMIAS IN PATIENTS WITH OBESITY DETECTED BY LONG-TERM CONTINUOUS AMBULATORY ECG MONITORING
通過長期連續(xù)動態(tài)心電圖監(jiān)測檢出的肥胖患者心律失常發(fā)生率

T. Battisti

1404. Coronary, Peripheral and Structural Interventions 05
北京時間：04:30
EVALULATING THE IMPACT OF OBESITY ON OUTCOMES IN PATIENTS IN STEMI: THE OBESITY PARADOX THROUGH A 7-YEAR NATIONWIDE ANALYSIS
評估肥胖對ST段抬高型心肌梗死患者結(jié)局的影響：通過七年全國性分析探討肥胖悖論

Prabhjot Hundal

1419. Heart Failure and Cardiomyopathies 05
北京時間：04:30
EFFICACY OF SGLT2 INHIBITORS IN HEART FAILURE WITH OBESITY: A CONVENTIONAL AND BAYESIAN META-ANALYSIS OF RANDOMIZED TRIALS
SGLT2抑制劑在肥胖合并心力衰竭患者中的療效：一項隨機試驗的傳統(tǒng)及貝葉斯薈萃分析

L. Freeman

1085. What's New in Nutrient Stimulated Hormone Therapies
北京時間：22:42
MIND AND HEART: CARDIOVASCULAR AND PSYCHIATRIC OUTCOMES WITH TIRZEPATIDE VS GLP-1 AGONISTS IN OBESITY
心智與心臟：替爾泊肽對比GLP-1激動劑在肥胖患者中的心血管及精神結(jié)局

U. Eziyi

北京時間：23:06
COMPARATIVE OUTCOMES OF GLP-1 RECEPTOR AGONISTS AND BARIATRIC SURGERY IN OBESE PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION
GLP-1受體激動劑與減重手術(shù)在射血分數(shù)降低的心力衰竭肥胖患者中的比較結(jié)局

A. K. Mahmoud

1088. Beyond Weight Loss: GLP-1 Agonists and Impact on Arrhythmias
北京時間：22:54
COMPARATIVE OUTCOMES OF GLP-1 RECEPTOR AGONISTS VERSUS BARIATRIC SURGERY IN PATIENTSUNDERGOING ATRIAL FIBRILLATION ABLATION
GLP-1受體激動劑對比減重手術(shù)在接受房顫消融患者中的比較結(jié)局

Divya Pate

北京時間：23:18
REAL WORLD IMPACT OF TIRZEPATIDE ON CLASS III OBESE PATIENTS UNDERGOING ATRIAL FIBRILLATION ABLATION
替爾泊肽對接受房顫消融的III級肥胖患者的真實世界影響

J. Haloot

1089. Treating Arrhythmias: Novel Inhaled Therapeutics, SGLT2 Inhibitors and GLP-1 Agonists
北京時間：23:18
GLP-1RA USE IN OSA PATIENTS IS ASSOCIATED WITH A LOWER INCIDENCE OF ATRIAL FIBRILLATION INDEPENDENT OF OBESITY
阻塞性睡眠呼吸暫停患者使用GLP-1受體激動劑與房顫發(fā)生率降低相關(guān)，且與肥胖無關(guān)

Y. Menassa

1090. Where You Live Matters: Geography, Disparities and Outcomes in Heart Failure
北京時間：22:54
TRENDS AND DISPARITIES IN HEART FAILURE MORTALITY AMONG UNITED STATES ADULTS WITH AND WITHOUT OBESITY: A 25 YEAR RETROSPECTIVE ANALYSIS
美國成人伴與不伴肥胖的心力衰竭死亡率趨勢與差異：一項25年回顧性分析

F. Sahil

1422. Cardiovascular Disease Prevention 06
北京時間：22:30
DEPRESSION?LINKED VARIATIONS IN CARDIOVASCULAR OUTCOMES AMONG OVERWEIGHT AND OBESE ADULTS
超重和肥胖成人中與抑郁相關(guān)的心血管結(jié)局變異

A. K. Carboo

1443. Heart Failure and Cardiomyopathies 06
北京時間：22:30
COMPARATIVE OUTCOMES OF GLP-1 RECEPTOR AGONISTS VS. SGLT2 INHIBITORS IN OBESE PATIENTS WITH HFPEF: A PROPENSITY-MATCHED ANALYSIS
GLP-1受體激動劑對比SGLT2抑制劑在肥胖射血分數(shù)保留的心力衰竭患者中的比較結(jié)局：一項傾向評分匹配分析

A. Naeem

270. Heart Failure and Obesity: Dual Epidemics, Single Strategy?
北京時間：23:45
The Weight of Heart Failure: Unpacking the Overlap with Obesity
心力衰竭的負擔：解析其與肥胖的重疊

Magdy Abdelhamid

北京時間：23:55
Labels That Matter: Rethinking How We Define Obesity and Heart Failure
重要的標簽：重新思考我們?nèi)绾味x肥胖與心力衰竭

Josephine Harrington

北京時間：00:05
Therapeutic Crossroads: Where HF and Obesity Management Meet
治療的十字路口：心力衰竭與肥胖管理的交匯點

Kate Cabral

北京時間：00:15
Clinic in Sync: Designing a Team-Based Approach to HF and Obesity
同步診所：設(shè)計基于團隊的心力衰竭與肥胖管理模式

Amanda Vest

03月30日

1446. Cardiovascular Disease Prevention 07
北京時間：00:00
ASSOCIATION OF C-REACTIVE PROTEIN-TRIGLYCERIDE-GLUCOSE INDEX WITH LIPOPROTEIN(A) LEVELS IN ADULTS WITH OBESITY
肥胖成人中C反應(yīng)蛋白-甘油三酯-葡萄糖指數(shù)與脂蛋白(a)水平的關(guān)聯(lián)

S. Ghay

北京時間：00:00
LINKING C-REACTIVE PROTEIN-TRIGLYCERIDE-GLUCOSE INDEX TO LIPOPROTEIN(A) AMONG WOMEN WITH OBESITY
肥胖女性中C反應(yīng)蛋白-甘油三酯-葡萄糖指數(shù)與脂蛋白(a)的關(guān)聯(lián)

S. Ghay

1464. Complex Clinical Cases: Cardiac Arrhythmias 07
北京時間：00:00
BEDSIDE ABLATION OF A LIFE-THREATENING ATRIAL FLUTTER WITH 1:1 CONDUCTION IN A MORBIDLY OBESE PATIENT
一例病態(tài)肥胖患者中1:1傳導(dǎo)的危及生命心房撲動的床旁消融治療

A. Saad

1467. Heart Failure and Cardiomyopathies 07
北京時間：00:00
SEVERE OBESITY PREDICTS EARLY MORTALITY AND CRITICAL CARE UTILIZATION AFTER PERCUTANEOUS VENTRICULAR ASSIST DEVICE (PVAD) SUPPORT
嚴重肥胖預(yù)測經(jīng)皮心室輔助裝置支持后的早期死亡率和重癥監(jiān)護資源使用

Muhammad Raffey Shabbir

北京時間：00:00
A META-ANALYSIS OF EFFECTIVENESS OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN PATIENTS WITH OBESITY AND HEART FAILURE WITH PRESERVED EJECTION FRACTION
GLP-1受體激動劑在肥胖合并射血分數(shù)保留的心力衰竭患者中有效性的薈萃分析

L. García-Mena

410. ACC Clinical Policy: From Guidelines to Expert Consensus in CVD Prevention
北京時間：01:05
2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on Medical Weight Management for Optimization of Cardiovascular Health
2025年簡明臨床指南：美國心臟病學會關(guān)于優(yōu)化心血管健康的醫(yī)學減重管理專家共識聲明

Olivia N. Gilbert

108. Cardiovascular Update For the Clinician I: A Symposium by Valentin Fuster
北京時間：02:03
The Obesity Epidemic - Bariatric Surgery and Pharmacotherapy: The Five Advances, Including Long Term Strategic Challenges
肥胖流行——減重手術(shù)與藥物治療：五項進展及長期戰(zhàn)略挑戰(zhàn)

Tim Garvey

281. Summing It Up For the CV Specialist: Evidence Review of Novel CKM Therapies
北京時間：01:20
Treating CVD in Patients With Obesity: New Evidence Informing Care
肥胖患者心血管疾病的治療：指導(dǎo)臨床護理的新證據(jù)

Abraham Michael Lincoff

北京時間：01:30
Understanding Recent Trial Evidence for Treating Obesity
理解近期治療肥胖的試驗證據(jù)

Ania Jastreboff

1116. Environment Influences on Prevention
北京時間：02:18
ENVIRONMENTAL PHTHALATE EXPOSURE AND EARLY-ONSET HYPERTENSION IN YOUNG ADULTS: THE ROLE OF OBESITY AND METABOLIC MODULATION - FINDINGS FROM NHANES 2006-2018
環(huán)境鄰苯二甲酸酯暴露與年輕成人早發(fā)性高血壓：肥胖和代謝調(diào)節(jié)的作用——基于NHANES 2006-2018的研究發(fā)現(xiàn)

R. Mansoor

1468. Featured Fields 08
北京時間：01:30
BURDEN OF OBESITY AND HYPERTENSION ON ADULT MORTALITY IN THE UNITED STATES: INSIGHTS FROM CDC WONDER
美國成人死亡率中肥胖和高血壓的負擔：來自CDC WONDER的見解

T. Fida

1475. Coronary, Peripheral and Structural Interventions 08
北京時間：01:30
PROJECTING THE BENEFITS OF GLP-1RA THERAPY IN OBESE PATIENTS WITHOUT DIABETES UNDERGOING COMPLEX PCI
預(yù)測GLP-1受體激動劑治療在接受復(fù)雜經(jīng)皮冠狀動脈介入治療的非糖尿病肥胖患者中的獲益

J. Nicolas

806. Young Investigator Awards Competition: Clinical Investigations
北京時間：02:35
GLP-1 RECEPTOR AGONISTS USE IN OBESE PATIENTS WITH STABLE HEART FAILURE WITH REDUCED EJECTION FRACTION: A TARGET-TRIAL EMULATION
GLP-1受體激動劑在穩(wěn)定期射血分數(shù)降低的心力衰竭肥胖患者中的應(yīng)用：一項目標試驗?zāi)M

Kuan-Yu Chi

1514. Heart Failure and Cardiomyopathies 09
北京時間：03:00
OBESITY PARADOX REVISITED THROUGH THE LENS OF FRAILTY
透過衰弱視角重新審視肥胖悖論

Viana Copeland

1517. Cardiovascular Disease Prevention 10
北京時間：04:30
CARDIOVASCULAR OUTCOMES OF GLP-1RA THERAPY IN OBESE NON-DIABETIC PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: A REAL-WORLD ANALYSIS
GLP-1受體激動劑治療在肥胖非糖尿病合并代謝功能障礙相關(guān)脂肪性肝病患者中的心血管結(jié)局：一項真實世界分析

M. Elnashar

北京時間：04:30
SEX, ADIPOSITY-RELATED ANTHROPOMETRICS, AND CLINICAL OUTCOMES IN CARDIOVASCULAR-KIDNEY-METABOLIC DISEASE
性別、肥胖相關(guān)人體測量學指標與心血管-腎臟-代謝疾病的臨床結(jié)局

J. Ostrominski

北京時間：04:30
RACE, ADIPOSITY-RELATED ANTHROPOMETRICS, AND CLINICAL OUTCOMES IN CARDIOVASCULAR-KIDNEY-METABOLIC DISEASE
種族、肥胖相關(guān)人體測量學指標與心血管-腎臟-代謝疾病的臨床結(jié)局

J. Ostrominski

北京時間：04:30
BENEFITS OF TIRZEPATIDE VERSUS BARIATRIC SURGERY ON MORTALITY, CARDIOVASCULAR DISEASE, AND SLEEP APNEA
替爾泊肽與減重手術(shù)在死亡率、心血管疾病及睡眠呼吸暫停方面的獲益

Ibrahim Mortada

1519. Ischemic Heart Diseases 10
北京時間：04:30
THE OBESITY PARADOX PERSISTS IN CHRONIC TOTAL OCCLUSION OF CORONARY ARTERIES: A PROPENSITY-MATCHED COHORT STUDY
肥胖悖論在冠狀動脈慢性完全閉塞中持續(xù)存在：一項傾向評分匹配隊列研究

S. Singh

1523. Coronary, Peripheral and Structural Interventions 10
北京時間：04:30
THIRTY-DAY READMISSION RATES, TIMING, PREDICTORS, AND COSTS AFTER CORONARY ARTERY BYPASS GRAFT SURGERY IN OBESE PATIENTS
肥胖患者冠狀動脈旁路移植術(shù)后的30天再入院率、時機、預(yù)測因素及費用

R. Ochani

1538. Heart Failure and Cardiomyopathies 10
北京時間：04:30
THE OBESITY PARADOX IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: A NATIONWIDE ANALYSIS OF OUTCOMES AND RESOURCE UTILIZATION (2016-2022)
射血分數(shù)保留的心力衰竭中的肥胖悖論：2016-2022年全國性結(jié)局與資源利用分析

Siddharth Agrawal

312. Beyond the Scale: Obesity and the Heart in the Age of GLP1s
北京時間：05:00
Heavy Hearts: Obesity and the Hidden Burden of HFpEF
沉重的心臟：肥胖與射血分數(shù)保留的心力衰竭的隱藏負擔

Milton Packer

北京時間：05:30
Weight Loss Medications: What is Coming on the Horizon?
減重藥物：未來有哪些新進展？

Abraham Michael Lincoff

1562. Heart Failure and Cardiomyopathies 11
北京時間：22:30
CARDIOVASCULAR OUTCOMES OF GLP-1 RA USE IN NON-OBESE DIABETIC NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY: A PROPENSITY MATCHED ANALYSIS
GLP-1受體激動劑在非肥胖糖尿病非梗阻性肥厚型心肌病中的心血管結(jié)局：一項傾向評分匹配分析

Efeturi Okorigba

北京時間：22:30
EFFECT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON HEART FAILURE WITH MILDLY REDUCED OR PRESERVED EJECTION FRACTION IN PATIENTS WITH OBESITY AND TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW AND META-ANALYSIS
GLP-1受體激動劑對肥胖合并2型糖尿病患者輕度降低或保留射血分數(shù)的心力衰竭的影響：一項系統(tǒng)評價與薈萃分析

B. Jeswani

336. Investigative Horizons I
北京時間：00:00
Anti-inflammatory Actions And Safety Of The NLRP3 Inhibitor VTX3232 Alone Or In Combination With Semaglutide In Participants With Obesity: A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study
NLRP3抑制劑VTX3232單藥或與司美格魯肽聯(lián)合用藥在肥胖受試者中的抗炎作用及安全性：一項2a期、多中心、隨機、雙盲、安慰劑對照研究

Peter Libby

03月31日

1565. Cardiovascular Disease Prevention 12
北京時間：00:00
CAGRILINTIDE-SEMAGLUTIDE (CAGRISEMA) VS SEMAGLUTIDE: SUPERIOR WEIGHT LOSS AND COMPARABLE SAFETY THROUGH SYNERGISTIC AMYLIN-GLP-1 CO-THERAPY: A META-ANALYSIS
卡格里林肽-司美格魯肽對比司美格魯肽：通過協(xié)同胰淀素-GLP-1聯(lián)合治療實現(xiàn)更優(yōu)減重效果及相當安全性：一項薈萃分析

R. Mannam

1586. Heart Failure and Cardiomyopathies 12
北京時間：00:00
THE VALUE OF CARDIOPULMONARY EXERCISE TESTING IN EVALUATING SUBCLINICAL CARDIAC DYSFUNCTION IN UNEXPLAINED DYSPNEA OVERWEIGHT PATIENTS
心肺運動試驗在評估不明原因呼吸困難超重患者亞臨床心功能不全中的價值

褚松筠 北京大學第一醫(yī)院

912. Highlighted Original Research: Cardiovascular Disease Prevention
北京時間：00:11
BARIATRIC METABOLIC SURGERY VERSUS GLP?1 RECEPTOR AGONISTS AMONG ADULTS WITH OBESITY: A PROPENSITY?MATCHED COHORT STUDY OF LONG?TERM MORTALITY AND CARDIOVASCULAR OUTCOMES
減重代謝手術(shù)對比GLP-1受體激動劑在肥胖成人中的長期死亡率和心血管結(jié)局：一項傾向評分匹配隊列研究

A. H. Hafez

1192. Impact of Digital Health and AI in Outpatient and Preventative Cardiology
北京時間：01:30
A DIGITAL CARDIOLOGY EMBEDDED OBESITY PLATFORM PRODUCES SUSTAINED CLINICAL AND FINANCIAL OUTCOMES, REDEFINING CARDIOVASCULAR PREVENTION
數(shù)字心臟病學嵌入式肥胖平臺產(chǎn)生持續(xù)的臨床和經(jīng)濟結(jié)局，重新定義心血管預(yù)防

Rami Bailony

1196. Adiposity-Driven Cardiometabolic Risk
北京時間：01:30
OBESITY ONSET IN EARLY ADULTHOOD VERSUS LATER LIFE: DIVERGENT CARDIOMETABOLIC PROFILES AND CARDIOVASCULAR RISK IN U.S. ADULTS, NHANES 2017-2020
成年早期與晚年發(fā)病的肥胖：美國成人中不同的心臟代謝特征與心血管風險，NHANES 2017-2020

S. Sarfraz

1588. Cardiovascular Disease Prevention 13
北京時間：01:30
LDL CHOLESTEROL AND CARDIOVASCULAR RISK ACROSS OBESITY AND METABOLIC SYNDROME PHENOTYPES: INSIGHTS FROM THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA)
低密度脂蛋白膽固醇與心血管風險在肥胖及代謝綜合征不同表型中的差異：來自多民族動脈粥樣硬化研究的見解

Beshoy Iskander

1595. Valvular Diseases 13
北京時間：01:30
IS THERE AN “OBESITY PARADOX” IN OUTCOMES FOLLOWING TRANSCATHETER AORTIC VALVE REPLACEMENT? A PROPENSITY-SCORE MATCHED ANALYSIS
經(jīng)導(dǎo)管主動脈瓣置換術(shù)后結(jié)局是否存在“肥胖悖論”？一項傾向評分匹配分析

H. Jain

1609. Heart Failure and Cardiomyopathies 13
北京時間：01:30
CARDIOVASCULAR OUTCOMES FOLLOWING BARIATRIC SURGERY IN OBESE PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY: A MULTICENTER PROPENSITY-MATCHED ANALYSIS
肥胖肥厚型心肌病患者減重術(shù)后的心血管結(jié)局：一項多中心傾向評分匹配分析

K. Awad

POCKETIN 將挑選重點研究，就已發(fā)布結(jié)果邀請專家陸續(xù)解讀

POCKETIN接受投稿，我們將為撰稿作者提供該研究的過往詳細資料，資料包括：原文、演講幻燈、官方新聞、演講視頻等素材。并根據(jù)稿件質(zhì)量支付稿費。

稿件將發(fā)表在POCKETIN、心關(guān)注微信公眾號上，并發(fā)表在國際期刊《翳望》（ISSN 2709-9105）上。同時，稿件將作為供稿提供給合作單位。

投稿請聯(lián)系：zhengsisi@medicaltelescope.cn 鄭思思

如發(fā)現(xiàn)文內(nèi)有誤請聯(lián)系我們

來源：ACC.26

POCKETIN

ACC.26

由蘇州工業(yè)園區(qū)東方華夏心血管健康研究院和醫(yī)望共同發(fā)起的POCKETIN項目將依托人工智能學術(shù)跟蹤系統(tǒng)，為全國廣大心血管醫(yī)師帶來及時全面的報道。

項目得到了醫(yī)師報、梅斯醫(yī)學、365醫(yī)學網(wǎng)、健康界、中華醫(yī)學信息導(dǎo)報、心關(guān)注、醫(yī)心、嚴道醫(yī)聲網(wǎng)等單位的大力支持。

▼更多精彩內(nèi)容，請長按二維碼▼

1. 相關(guān)學術(shù)信息由醫(yī)望自主研發(fā)的人工智能學術(shù)跟蹤機器人提供。

2. 相關(guān)學術(shù)信息由醫(yī)望提供的醫(yī)學翻譯機器人完成翻譯后邀請臨床醫(yī)師進行再次校對。
3. 如有內(nèi)容上的不準確請微信聯(lián)系我們（zhengsisi@medicaltelescope.cn）

4. POCKETIN引入人工智能大語言模型，攜手專業(yè)編輯團隊，開啟會議速遞全新體驗。